Patents by Inventor Kinji Takada

Kinji Takada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5224021
    Abstract: A surface-mount network device which is to be mounted on a mounting substrate is disclosed. This device has an insulating substrate having wirings and passive elements. A plurality of lead terminals sandwich the insulating substrate from an end face of the insulating substrate. Terminal connection conductors are formed on the main surfaces of the insulating substrate and connect the lead terminals and at least one of the wirings and the passive elements. Sealing material cover at least connecting portions between the terminal connection conductors and the lead terminals. End portions of the lead terminals are bent to extend in a direction substantially parallel to the mounting substrate. This device is to be mounted vertically on the mounting substrate through the bent end portions of the lead terminals.
    Type: Grant
    Filed: October 19, 1990
    Date of Patent: June 29, 1993
    Assignee: Matsushita Electric Industrial Co., Ltd.
    Inventors: Kinji Takada, Kazuo Oishi, Syozo Yamashita, Koji Nishida
  • Patent number: 5158886
    Abstract: A hybridoma producing a monoclonal antibody specific for free N-acetylneuraminic acid or beta glycoconjugates thereof, is herein disclosed. The hybridoma can be generated by fusing (i) B cells of lymphocytes obtained by immunizing an animal with an N-acetylneuraminic acid or a beta-glycoconjugate thereof, and (ii) myeloma cells.
    Type: Grant
    Filed: November 8, 1988
    Date of Patent: October 27, 1992
    Assignee: MECT Corporation
    Inventors: Atsushi Kawamura, Isao Suda, Kinji Takada, Masayoshi Ito, Yoshiyasu Shitori
  • Patent number: 5142028
    Abstract: A monoclonal antibody specifically recognizes an epitope or an antigenic determinant represented by the following formula and specifically reacts therewith: ##STR1## The monoclonal antibody can be obtained by cultivating hybridoma cells which can be generated by a method comprising cell-fusing (A) B cells or lymphocytes obtained by immunizing an animal with a substance involving the epitope or the antigenic determinant represented by the foregoing formula and (B) myeloma cells. The monoclonal antibody shows high specificity to ganglioside GQ.sub.1b and ganglioside GT.sub.1a having a specific epitope and thus can detect the epitope in high sensitivity. Therefore, the antibody can be used for the elucidation of sugar chain's roles in cell functions and for studying the development of animals. Moreover, the monoclonal antibody would have various clinical applications.
    Type: Grant
    Filed: July 10, 1989
    Date of Patent: August 25, 1992
    Assignee: Mect Corporation
    Inventors: Yoshitaka Nagai, Hideki Yamamoto, Kinji Takada, Masayoshi Ito
  • Patent number: 5141864
    Abstract: A hybridoma capable of producing a monoclonal antibody specific to a sialic acid containing glycolipid carrying N-acetylneuraminic acid residue having alpha 2.fwdarw.3 linkage is herein disclosed. The hybridoma can be generated by fusing (i) B cells or lymphocytes obtained by immunizing an animal with a sialic acid containing glycolipid carrying N-acetylneuraminic acid residue having alpha 2.fwdarw.3 linkage and (ii) myeloma cells. The monoclonal antibody produced by the hybridoma can be used for purifying gangliosides, for treating patients suffering from melanoma and for diagnosing sera.
    Type: Grant
    Filed: November 14, 1988
    Date of Patent: August 25, 1992
    Assignee: Mect Corporation
    Inventors: Yoshitaka Nagai, Hideki Yamamoto, Kinji Takada, Ito, Yoshiyasu Shitori
  • Patent number: 4436904
    Abstract: Novel cephalosporin derivatives are described which have excellent antibiotic activity against pathogenic bacteria belonging to the Pseudomonas, Serratia and Enterobacter. The compounds have general formula ##STR1## in which R is hydrogen, acyloxy, carbamoyloxy, a substituted or unsubstituted pyridinium group or a group -S-Het in which Het represents a substituted or unsubstituted, hetero atom-containing, 5- or 6-membered heterocyclic ring, R' is hydrogen, alkali metal, an organic amine or an ester moiety, R.sub.1 and R.sub.2 are the same or different and are hydrogen or a lower alkyl and B stands for a 1,4-cyclohexadienyl group, a group ##STR2## in which Y is hydrogen, --OH or ##STR3## in which R.sub.5 is an alkyl of 1 to 5 carbon atoms, aryl or alkoxy having 1 to 4 carbon atoms, Z stands for hydrogen or halogen and p is an integer of 1 or 2, a furan group or a thiophene group. Methods of preparation are described.
    Type: Grant
    Filed: January 6, 1982
    Date of Patent: March 13, 1984
    Assignee: Kanto Ishi Pharmaceutical Co., Ltd.
    Inventors: Shigeo Shimizu, Hiroyuki Takano, Shoji Yoshimura, Kinji Takada